Aura Maria Hurtado-Puerto

Dr. Aura Maria Hurtado-Puerto

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Clinical Therapeutics
Verified
Journal Article
Closed access
Aura Maria Hurtado-PuertoAura Maria Hurtado-Puerto
Aura Maria Hurtado-Puerto
KNKimberly Nestor
Kimberly Nestor
Mark EldaiefMark Eldaief
Mark Eldaief
JCJoan A. Camprodon
Joan A. Camprodon

1 November 2017 in Frontiers in Neurology
Verified
Journal Article
Open access
ATAurore Thibaut
Aurore Thibaut
CRCristina Russo
Cristina Russo
Aura Maria Hurtado-PuertoAura Maria Hurtado-Puerto
Aura Maria Hurtado-Puerto
JMJorge Leon Morales-Quezada
Jorge Leon Morales-Quezada
ADAlícia Deitos
Alícia Deitos
Felipe FregniFelipe Fregni
Felipe Fregni
Objective: Chronic Visceral Pain (CVP) syndromes are persistently painful disorders with a remarkable lack of effective treatment options. This study aimed at evaluating the effects of different neuromodulation techniques in patients with CVP on cortical activity, through electreocephalography (EEG) and on pain perception, through clinical tests. Methods: In this pilot crossover randomized controlled study, adults with chronic visceral pain (>3months) received 4 interventions in a randomized order: 1. active transcranial Pulsed Current Stimulation (tPCS) and active transcranial Direct Current Stimulation (tDCS) combined, 2. active tPCS and sham tDCS, 3. Active tDCS and sham tPCS and 4. Sham tPCS and sham tDCS. Before and after each intervention resting state Quantitative Electroencephalography (qEEG) and pain assessments were performed. Results were compared to a cohort of 47 healthy controls. Results: We enrolled six patients with CVP for a total of 21 visits completed. Compared to healthy participants, patients with CVP showed altered cortical activity characterized by increased power in theta, alpha and beta bands, and a significant reduction in the alpha/beta ratio. Regarding tES, the combination of tDCS with tPCS had no effect on power in any of the bandwidths, nor brain regions. Comparing tPCS with tDCS alone, we found that tPCS induced higher increase in power within the theta and alpha bandwidths. Conclusion: This study confirms that patients with CVP present abnormal EEG-indexed cortical activity compared to healthy controls. Moreover, we showed that combining two types of neurostimulation techniques had no effect, whereas, the two interventions, when applied individually, have different neural signatures.

20 March 2018 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
EREduardo Augusto Rosa
Eduardo Augusto Rosa
Aura Maria Hurtado-PuertoAura Maria Hurtado-Puerto
Aura Maria Hurtado-Puerto
DFDenise Falc�O
Denise Falc�O
ABAline Patricia Brietzke
Aline Patricia Brietzke
LFLuiz Eduardo de Almeida Prado Franceschi
Luiz Eduardo de Almeida Prado Franceschi
RARivadávio Fernandes Batista Amorim
Rivadávio Fernandes Batista Amorim
The association of oral lichen planus (OLP) lesions with malignant transformation risk has remained a controversial topic and is of clinical importance. Therefore, the present study evaluated the expression levels of p16, Ki‑67, budding uninhibited by benzimidazoles 3 (Bub‑3) and sex‑determining region Y‑related high mobility group box 4 (SOX4), and their roles as precancerous biomarkers in OLP. A retrospective study was performed, in which tissue blocks of OLP, oral dysplasia (OD), cutaneous lichen planus (CLP) and oral fibrous hyperplasia (OFH) were used (n=120). A positivity index (PI) for p16, BUB3, Ki‑67 and SOX4 expression was calculated in each group. The PI for p16 was 20.65% for OLP, 7.85% for OD, 86.59% for CLP and 11.8% for OFH, and the difference between these groups was statistically significant (P<0.001). PIs of Ki‑67 were indicated as 11.6% for OLP, 14.4% for OD, 8.24% for CLP and 5.5% for OFH, and a statistically significant difference was observed between the groups (P<0.001). Notably, the expression levels of BUB3 were not statistically different among groups. The highest expression levels of SOX4 were identified in CLP (P<0.001 vs. OLP/CLP; P=0,001 vs. CLP/OD). The determined expression levels of p16 and Ki‑67 suggest that specific OLP lesions may have an intermediate malignant potential and should be carefully followed up. The intense SOX4 staining in CLP indicated a different proliferation pattern of epithelium compared with oral mucosa cells. These findings suggest that SOX4 expression may also be associated with the different clinical courses of OLP and CLP.

7 October 2024 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
Akila S WeerasekeraAkila S Weerasekera
Akila S Weerasekera
DCDavid Richer Araujo Coelho
David Richer Araujo Coelho
EREva-Maria Ratai
Eva-Maria Ratai
KCKatherine Collins
Katherine Collins
Aura Maria Hurtado-PuertoAura Maria Hurtado-Puerto
Aura Maria Hurtado-Puerto
DIDan Vlad Iosifescu
Dan Vlad Iosifescu

13 July 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
DIDan Vlad Iosifescu
Dan Vlad Iosifescu
XSXiaotong Song
Xiaotong Song
MGMaia Gersten
Maia Gersten
AAArwa Adib
Arwa Adib
YCYoonju Cho
Yoonju Cho
PCPaolo Cassano
Paolo Cassano
Background: Alzheimer’s disease’s (AD) prevalence is projected to increase as the population ages and current treatments are minimally effective. Transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light penetrates into the cerebral cortex, stimulates the mitochondrial respiratory chain, and increases cerebral blood flow. Preliminary data suggests t-PBM may be efficacious in improving cognition in people with early AD and amnestic mild cognitive impairment (aMCI). Methods: In this randomized, double-blind, placebo-controlled study with aMCI and early AD participants, we will test the efficacy, safety, and impact on cognition of 24 sessions of t-PBM delivered over 8 weeks. Brain mechanisms of t-PBM in this population will be explored by testing whether the baseline tau burden (measured with 18F-MK6240), or changes in mitochondrial function over 8 weeks (assessed with 31P-MRSI), moderates the changes observed in cognitive functions after t-PBM therapy. We will also use changes in the fMRI Blood-Oxygenation-Level-Dependent (BOLD) signal after a single treatment to demonstrate t-PBM-dependent increases in prefrontal cortex blood flow. Conclusion: This study will test whether t-PBM, a low-cost, accessible, and user-friendly intervention, has the potential to improve cognition and function in an aMCI and early AD population.

13 January 2023 in Photonics
Verified
Journal Article
Open access
PDF file
DIDan Vlad Iosifescu
Dan Vlad Iosifescu
KCKatherine Collins
Katherine Collins
Aura Maria Hurtado-PuertoAura Maria Hurtado-Puerto
Aura Maria Hurtado-Puerto
MIMolly K. Irvin
Molly K. Irvin
JCJulie A. Clancy
Julie A. Clancy
PCPaolo Cassano
Paolo Cassano
We report on the rationale and design of an ongoing National Institute of Mental Health (NIMH) sponsored R61-R33 project in major depressive disorder (MDD). Current treatments for MDD have significant limitations in efficacy and side effect burden. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. This project focuses on the adjunctive use of the transcranial photobiomodulation (tPBM) with near-infrared (NIR) light for the treatment of MDD. tPBM with NIR light penetrates robustly into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow (CBF). In the R61 phase, we will conduct target engagement studies to demonstrate dose-dependent effects of tPBM on the prefrontal cortex (PFC) CBF, using the increase in fMRI blood-oxygenation-level-dependent (BOLD) signal levels as our Go/No-go target engagement biomarker. In the R33 phase, we will conduct a randomized clinical trial of tPBM vs. sham in MDD to establish the target engagement and evaluate the association between changes in the biomarker (BOLD signal) and changes in clinical symptoms, while also collecting important information on antidepressant effects, safety, and tolerability. The study will be done in parallel at New York University/the Nathan Kline Institute (NYU/NKI) and at Massachusetts General Hospital (MGH). The importance of this study is threefold: 1. it targets MDD, a leading cause of disability worldwide, which lacks adequate treatments; 2. it evaluates tPBM, which has a well-established safety profile and has the potential to be safe in at-home administration; and 3. it uses fMRI BOLD changes as a target engagement biomarker. If effects are confirmed, the present study will both support short-term clinical development of an easy to scale device for the treatment of MDD, while also validating a biomarker for the development of future, novel modulation strategies.